NEW YORK, Jan 23 (Reuters) - Martin Shkreli, known for once hiking the price of a life-saving drug more than 4,000%, cannot return to the pharmaceutical industry after a federal appeals court on ...
The Supreme Court is seen on Monday, Oct. 7, 2024, in Washington. (AP Photo/Mariam Zuhaib) (Mariam Zuhaib, Copyright 2024 The Associated Press. All rights reserved ...
Investor Martin Shkreli’s big biotech short position is blowing up after the stock’s monumental rally over the past week, following a major clinical catalyst. Popularly known as “Pharma bro,” Shkreli ...
Oct 7 (Reuters) - The U.S. Supreme Court declined on Monday to hear former pharmaceutical company CEO Martin Shkreli's challenge to a $64.6 million financial penalty imposed by a judge after he raised ...
In a recent X Spaces session hosted by Mario Nawfal, Shkreli revealed that Barron Trump approached him in April to help launch the Solana-based token, now valued at $158 million, according to Dextools ...
Martin Shkreli, the notorious former CEO of Turing Pharmaceuticals and convicted securities fraudster, will still be banned from working in the pharmaceutical industry after a federal appeals court in ...
The Supreme Court on Monday rejected an appeal from Martin Shkreli, who was once dubbed “Pharma Bro” after jacking up the price of a lifesaving drug. Shkreli appealed an order to return $64.6 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback